v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities:    
Net loss $ (4,461,895) $ (3,964,601)
Changes in operating assets and liabilities:    
Prepaid expenses and other (227,877) (219,593)
Research and development supplies 299,020 200,910
Accounts payable 911,959 451,389
Other current liabilities 266,904 (813,728)
Net cash used in operating activities (3,138,457) (4,161,424)
Cash flows from financing activities:    
Net proceeds from issuances of common stock 13,356,857 6,028,102
Net cash provided by financing activities 13,356,857 6,028,102
Net increase in cash and cash equivalents 10,218,400 1,866,678
Cash and cash equivalents, beginning of period 7,830,855 1,601,660
Cash and cash equivalents, end of period 18,049,255 3,468,338
Excluding ELOC Purchase Agreement [Member]    
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation $ 73,432 $ 184,199